Liao Pei-Ya, Ou Wei-Fan, Su Kang-Yi, Sun Ming-Hsi, Huang Chih-Mei, Chen Kun-Chieh, Hsu Kuo-Hsuan, Yu Sung-Liang, Huang Yen-Hsiang, Tseng Jeng-Sen, Yang Tsung-Ying, Chang Gee-Chen
Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan.
Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei 100, Taiwan.
Cancers (Basel). 2022 Jun 7;14(12):2824. doi: 10.3390/cancers14122824.
We aim to evaluate the influence of the timing of leptomeningeal metastasis (LM) occurrence on the outcome of -mutant lung adenocarcinoma and to explore the predictors of detectable mutation in the cerebrospinal fluid (CSF).
-mutant lung adenocarcinoma patients with cytologically confirmed LM were included for analysis. mutation in CSF was detected by MALDI-TOF MS plus PNA.
A total of 43 patients was analyzed. Of them, 8 (18.6%) were diagnosed with LM prior to first-line EGFR-TKI treatment (early onset), while 35 patients (81.4%) developed LM after first-line EGFR-TKI treatment (late onset). Multivariate analysis suggested that both late-onset LM (aHR 0.31 (95% CI 0.10-0.94), = 0.038) and a history of third-generation EGFR-TKI treatment (aHR 0.24 (95% CI 0.09-0.67), = 0.006) independently predicted a favorable outcome. mutation detection sensitivity in CSF was 81.4%. The radiological burden of LM significantly correlated with CSF tumor cell counts ( = 0.013) with higher CSF tumor cell counts predicting a higher detection sensitivity of mutation ( = 0.042).
Early onset LM was an independently poor prognostic factor. A higher radiological severity score of LM could predict higher tumor cell counts in CSF, which in turn were associated with a higher detection rate of mutation.
我们旨在评估软脑膜转移(LM)发生时间对EGFR突变型肺腺癌预后的影响,并探索脑脊液(CSF)中可检测到EGFR突变的预测因素。
纳入经细胞学确诊为LM的EGFR突变型肺腺癌患者进行分析。采用基质辅助激光解吸电离飞行时间质谱(MALDI-TOF MS)加肽核酸(PNA)检测CSF中的EGFR突变。
共分析43例患者。其中,8例(18.6%)在一线EGFR-TKI治疗前被诊断为LM(早发),而35例患者(81.4%)在一线EGFR-TKI治疗后发生LM(晚发)。多因素分析表明,晚发LM(调整后风险比[aHR] 0.31[95%置信区间(CI)0.10 - 0.94],P = 0.038)和第三代EGFR-TKI治疗史(aHR 0.24[95% CI 0.09 - 0.67],P = 0.006)均独立预测良好预后。CSF中EGFR突变检测敏感性为81.4%。LM的影像学负担与CSF肿瘤细胞计数显著相关(P = 0.013),CSF肿瘤细胞计数越高,EGFR突变检测敏感性越高(P = 0.042)。
早发LM是独立的不良预后因素。LM较高的影像学严重程度评分可预测CSF中较高的肿瘤细胞计数,而这又与EGFR突变的较高检出率相关。